A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.
Advanced Solid Tumor
DRUG: SPH7485
DLT(Dose-limiting toxicity), Measurement of DLT of SPH7485 in all subjects, Approximately 24 days|Maximum tolerated dose（MTD）, Measurement of MTD of SPH7485 in all subjects, Approximately 24 days|Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Approximately 2 years
ORR(Objective Response Rate), Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1., Approximately 2 years|DoR(Duration of response), DOR was defined as the time interval between the date of the first documented response (CR or PR) and the date of the first documented disease progression or death due to any cause, Approximately 2 years|DCR(Disease Control Rate), DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease, Approximately 2 years|PFS(Progression-free survival), PFS was defined as the time interval between study treatment initiation and the first occurrence of progression disease or death, whichever occurred first., Approximately 2 years|PK(Pharmacokinetics):Tmax, Time to peak plasma concentration (Tmax), Approximately 3 days|PK(Pharmacokinetics):Cmax, Maximum serum concentration(Cmax), Approximately 3 days|PK(Pharmacokinetics):AUC, Area under the plasma concentration versus time curve (AUC), Approximately 3 days
To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.